%PDF-1.4
%
46 0 obj
<>
endobj
43 0 obj
<>
endobj
302 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-07T11:16:51Z
2024-03-28T04:25:28-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T04:25:28-07:00
application/pdf
Heather
200301.january
uuid:f4480279-1dd1-11b2-0a00-8f0827bd3700
uuid:f448027b-1dd1-11b2-0a00-5b0000000000
endstream
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
47 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 22 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
14 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
313 0 obj
[318 0 R]
endobj
314 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.11369 Tw 9.7 0 0 10 54.3 465.1695 Tm
[(responses to 3 dif)18 (ferent endothelium dependent vasodilators)]TJ
-0.00301 Tw 0 -1.2 TD
(compared to controls. It is unlikely that these findings are due)Tj
0.0351 Tw T*
(to defects in 3 distinct receptor types. It is possible that these)Tj
0.13921 Tw T*
(results are due to a generalized defect at the cellular mem-)Tj
0.02499 Tw T*
(brane level, but this is hypothetical.)Tj
0.0145 Tw 1.2062 -1.18 Td
(In a recent investigation)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 159.8783 408.6695 Tm
(17)Tj
-0.00011 Tc 0.0145 Tw 9.7 0 0 10 166.1833 405.3695 Tm
(, we found that intraarterial infu-)Tj
0.13049 Tw -11.5344 -1.18 Td
[(sion of L-ar)18 (ginine, the endothelial substrate for nitric oxide)]TJ
0.3067 Tw 0 -1.18 TD
[(formation, significantly reduced RP)-520 (caused by laboratory)]TJ
0.2449 Tw T*
[(cooling in patients with SSc. )18 (This suggests, but does not)]TJ
0.0493 Tw T*
(prove, that the mechanism for nitric oxide formation is func-)Tj
0.022 Tw T*
[(tioning normally)65 (, at least at a level suf)18 (ficient to reduce symp-)]TJ
0 Tw T*
(toms.)Tj
0.04671 Tw 1.2062 -1.18 Td
(It is possible that the impaired responses to methacholine,)Tj
0.15131 Tw -1.2062 -1.18 Td
[(substance P)111 (, and bradykinin are due to a defect in a signal)]TJ
0.2007 Tw T*
[(transduction pathway common to these receptors. )18 (There is)]TJ
0.16251 Tw T*
(evidence that the protein tyrosine kinase pathway mediates)Tj
0.243 Tw T*
(responses to all three)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 142.9747 278.8697 Tm
(18)Tj
-0.00011 Tc 0.243 Tw 9.7 0 0 10 149.2796 275.5697 Tm
[(. Moreover)40 (, this pathway has been)]TJ
0.12469 Tw -9.7917 -1.18 Td
(implicated in cold induced vascular contraction in 2 animal)Tj
0 Tw T*
(models)Tj
0.0004 Tc 6.3 0 0 6.5 82.3178 255.2697 Tm
(19,20)Tj
-0.00011 Tc 0.0145 Tw 9.7 0 0 10 96.5039 251.9697 Tm
(, and it has been hypothesized that this mechanism)Tj
0.28951 Tw -4.3509 -1.18 Td
(is involved in RP)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 129.8183 243.4697 Tm
(20)Tj
-0.00011 Tc 0.28951 Tw 9.7 0 0 10 136.1233 240.1696 Tm
(. Inhibitors of protein tyrosine kinase)Tj
0.1946 Tw -8.4354 -1.18 Td
(reversed cold induced contraction of lamb middle cerebral)Tj
0.0199 Tc 0.42821 Tw T*
[(artery)65 (, while compounds that potentiate this pathway)]TJ
-0.00011 Tc 0.18291 Tw T*
(increased the cold induced contraction)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 210.5968 208.0698 Tm
(19)Tj
-0.00011 Tc 0.18291 Tw 9.7 0 0 10 216.9018 204.7697 Tm
[(. )18 (W)80 (e found similar)]TJ
0.1391 Tw -16.7631 -1.18 Td
[(ef)18 (fects in rat tail artery)65 (, which were significantly greater in)]TJ
0.1032 Tw T*
(female compared to male rats)Tj
0.00079 Tc 0 Tw 6.3 0 0 6.5 173.022 184.4698 Tm
(20)Tj
-0.00011 Tc 0.1032 Tw 9.7 0 0 10 179.327 181.1698 Tm
[(. )18 (Thus, it is possible that the)]TJ
0.0513 Tw -12.8894 -1.18 Td
(protein tyrosine kinase pathway mediates cold induced vaso-)Tj
0.11 Tw T*
[(constriction in RP)-323 (and SSc. However)40 (, considerable research)]TJ
0.02499 Tw T*
(would be needed to verify this hypothesis.)Tj
-0.0067 Tw 1.2062 -1.2 Td
[(W)80 (e found that the endothelium dependent compounds sub-)]TJ
-0.0304 Tw -1.2062 -1.2 Td
[(stance P)-183 (and bradykinin produced the expected vasodilation in)]TJ
0.05251 Tw 0 -1.2 TD
[(healthy subjects but vasoconstriction in patients with RP)-266 (and)]TJ
0.0851 Tw T*
[(SSc. )18 (The responses to sodium nitroprusside, an endothelium)]TJ
0.0199 Tc 0.3974 Tw T*
[(independent vasodilator)40 (, were similar in both groups.)]TJ
-0.00011 Tc 0.1129 Tw T*
[(T)70 (ogether with previous research, these findings suggest that)]TJ
0.00391 Tw 27.2165 63.9392 Td
[(the vascular defect in Raynaud\325)55 (s phenomenon with scleroder-)]TJ
0.0807 Tw T*
(ma does not lie at the receptor level, but possibly in a distal)Tj
0.02499 Tw T*
[(signal transduction pathway)65 (.)]TJ
/T1_1 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 325 655.1616 Tm
[(1.)-875 (Freedman RR, Sabhawal SC, Desai N, )18 (W)80 (enig P)111 (, Mayes M.)]TJ
1.675 -1.25 Td
[(Increased alpha-adrener)18 (gic responsiveness in idiopathic Raynaud\325)55 (s)]TJ
0 -1.25 TD
[(disease. )55 (Arthritis Rheum 1989;32:61-5.)]TJ
-1.675 -1.25 Td
[(2.)-875 (Freedman RR, Moten M, Migaly P)111 (, Mayes M. Cold-induced)]TJ
1.675 -1.25 Td
[(potentiation of alpha-2-adrener)18 (gic vasoconstriction in primary)]TJ
T*
[(Raynaud\325)55 (s disease. )55 (Arthritis Rheum 1993;36:685-90.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Freedman RR, Baer RP)111 (, Mayes M. Blockade of vasospastic attacks)]TJ
1.675 -1.25 Td
[(by alpha-2-adrener)18 (gic but not alpha-1-adrener)18 (gic antagonists in)]TJ
T*
[(idiopathic Raynaud\325)55 (s disease. Circulation 1995;92:1448-51.)]TJ
-1.675 -1.25 Td
[(4.)-875 (V)111 (ajda K, Kadar )55 (A, Kali )55 (A, Urai L. Ultrastructural investigations of)]TJ
1.675 -1.25 Td
[(finger pulp biopsies: )55 (A)-220 (study of 31 patients with Raynaud\325)55 (s)]TJ
T*
(syndrome. Ultrastruc Pathol 1982;80:175-86.)Tj
-1.675 -1.25 Td
[(5.)-875 (Khan F)80 (, Litchfield SJ, McLaren M, )18 (V)111 (eale DJ, Littleford RC, Belch)]TJ
1.675 -1.25 Td
[(JJF)80 (. Oral L-ar)18 (ginine supplementation and cutaneous vascular)]TJ
T*
[(responses in patients with primary Raynaud\325)55 (s phenomenon.)]TJ
T*
(Arthritis Rheum 1997;40:352-7.)Tj
-1.675 -1.25 Td
[(6.)-875 (Ringqvist )55 (A, Jonason )18 (T)74 (, Leppert J, Ringqvist I. Non-invasive)]TJ
1.675 -1.25 Td
(investigation of endothelium-dependent dilatation of the brachial)Tj
T*
[(artery in women with primary Raynaud\325)55 (s phenomenon. Clin Sci)]TJ
0 Tc 0 Tw T*
(1998;94:239-43.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (Rodnan GP)111 (, Myerowitz, RL, Justh GO. Morphologic changes in)]TJ
1.675 -1.25 Td
(digital arteries of patients with progressive systemic sclerosis)Tj
T*
[(\(scleroderma\) and Raynaud\325)55 (s phenomenon. Medicine 1980;)]TJ
0 Tc 0 Tw T*
(59:393-408.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875 (Norton )18 (WL, Nardo JM. )18 (V)111 (ascular disease in progressive systemic)]TJ
1.675 -1.25 Td
[(sclerosis \(scleroderma\). )55 (Ann Intern Med 1970;73:317-24.)]TJ
-1.675 -1.25 Td
[(9.)-875 (Freedman RR, Gir)18 (gis R, Mayes MD. Endothelial and adrener)18 (gic)]TJ
1.675 -1.25 Td
[(dysfunction in Raynaud\325)55 (s phenomenon and scleroderma. )]TJ
T*
(J Rheumatol 1999;26:2386-8.)Tj
-2.175 -1.25 Td
[(10.)-875 (Ruschitzka FT)74 (, Noll G, L\237scher )18 (TF)80 (. )18 (The endothelium in coronary)]TJ
2.175 -1.25 Td
(artery disease. Cardiology 1997;88 Suppl 3:3-19.)Tj
-2.1381 -1.25 Td
[(1)37 (1.)-875 (American Rheumatism )55 (Association. Preliminary criteria for the)]TJ
2.1381 -1.25 Td
(classification of systemic sclerosis \(scleroderma\). N Engl J Med)Tj
0 Tc 0 Tw T*
(1990;323:1486-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Duf)18 (f RS. )55 (Adrenaline sensitivity of peripheral blood vessels in)]TJ
2.175 -1.25 Td
(human hypertension. Br Heart J 1957;19:45-55.)Tj
-2.175 -1.25 Td
[(13.)-875 (W)40 (iner BJ, Brown DR, Michels KM. Statistical principles in)]TJ
2.175 -1.25 Td
[(experimental design. New )37 (Y)100 (ork: McGraw-Hill; 1991.)]TJ
-2.175 -1.25 Td
[(14.)-875 (Cof)18 (fman JD, Cohen RA. Intra-arterial vasodilator agents to reverse)]TJ
2.175 -1.25 Td
[(human finger vasoconstriction. Clin Pharmacol )18 (Ther 1987;)]TJ
0 Tc 0 Tw T*
(41:574-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875 (Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor)]TJ
2.175 -1.25 Td
[(response to intravenous infusion of substance P)-238 (and glyceryl)]TJ
T*
(trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990;8:561-5.)Tj
-2.175 -1.25 Td
[(16.)-875 (Cailes J, )18 (W)40 (inter S, du Bois RM, Evans )18 (TW)92 (. Defective endothelially)]TJ
2.175 -1.25 Td
(mediated pulmonary vasodilation in systemic sclerosis. Chest)Tj
0 Tc 0 Tw T*
[(1998;1)37 (14:178-84.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Freedman RR, Gir)18 (gis R, Mayes MD. )55 (Acute ef)18 (fect of nitric oxide on)]TJ
2.175 -1.25 Td
[(Raynaud\325)55 (s phenomenon in scleroderma [letter]. Lancet)]TJ
0 Tc 0 Tw T*
(1999;354:739.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875 (Kitazono )18 (T)74 (, Ibayashi S, Nagao )18 (T)74 (, Fujii K, Kagiyama )18 (T)74 (, Fujishima)]TJ
2.175 -1.25 Td
(M. Role of tyrosine kinase in dilator responses of rat basilar artery)Tj
T*
(in vivo. Hypertension 1998;31:861-5.)Tj
-2.175 -1.25 Td
[(19.)-875 (W)80 (agerle LC, Kim SJ, Russo P)111 (. Protein tyrosine kinase signaling in)]TJ
2.175 -1.25 Td
[(cold-stimulated contraction of newborn lamb cerebral arteries. )55 (Am)]TJ
0 Tc T*
(J Physiol 1996;270:H645-50.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875 (Furspan PB, Freedman RR. Ef)18 (fect of modulators of protein tyrosine)]TJ
2.175 -1.25 Td
[(kinase activity on gender)20 (-related dif)18 (ferences in vascular reactivity)]TJ
T*
(at reduced temperature. J Cardiovasc Pharmacol 1998;32:728-35.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Fr)37 (eedman, et al:)-250 (Abnormal endothelial r)37 (esponses in SSc)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(121)Tj
ET
Q
Q
q
1 0 0 1 22 0 cm
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
79.25 58.75 407.5 -10.83 re
f*
0 0 0 1 K
0.5 w
79.25 58.75 407.5 -10.83 re
S
Q
Q
q
47 721 255 -220 re
W* n
q
/Fm0 Do
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc 0.0217 Tw 7.76 0 0 8 54.3 501.5364 Tm
[(Figur)37 (e 3.)]TJ
/T1_0 1 Tf
3.9779 0 Td
[(Finger blood flow responses to intraarterial substance P)111 (. *p < 0.05,)]TJ
0 Tc 0.02499 Tw -3.9779 -1.25 Td
[(**p < 0.005, )55 (ANOV)129 (A.)]TJ
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_3 8 Tf
106.328 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
26 0 obj
<>stream
8;Z\7!HQ+$#iu"-j?)`S/tepO@a`QHd5J[2F6i7O5afCWNR%s#L@b?5]a&>&pkuf2
@s^mOT7>RpmMCUQ83S0X-O!Q'
"q%>ZE!!t]P#\`D3iN._K^?"Ijc`]D!SXkr:h]32@SO"(TnNt1fb\L#E:F=]@jc+LkP;E:p6@61#2/sQ>V$9ADA']fU=%UZ+?'o*](q/lKNF^Eh3'g7T.?e43!(:
XYhb:/L5*^Bs8eoZjW;\0N!&Rk&'b)hJM.''r3'CrdPdGrESenT%uo2$7];UID:jX
@`MBi]r2'VqnSXl3a\>lij)$2a"08"4"Ki:GH(lq]W@)GMh@8@LgdkX_CU1[;L4a#&eec:*^rDic-kR^:!1#hE]P2d`OpV,`Qc
o>25bO?fcMY!6[A25,TsX0,TS>MBpa.bB$0V:?cpchEeq@L.'gq58JZU"+2!n]cO4
q[\^Z!<
endstream
endobj
30 0 obj
[/Indexed/DeviceRGB 255 29 0 R]
endobj
29 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
21 0 obj
<>stream
H1
@g2W
DTDsga